Issued Patents All Time
Showing 1–17 of 17 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12285427 | Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor | Remi-Martin Laberge, Judith Campisi, Marco Demaria, Bennett G. Childs, Nathaniel David +1 more | 2025-04-29 |
| 11963957 | Treating cardiovascular disease by selectively eliminating senescent cells | Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David +2 more | 2024-04-23 |
| 11351167 | Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue | Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, James L. Kirkland +3 more | 2022-06-07 |
| 10517866 | Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor | Remi-Martin Laberge, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David +3 more | 2019-12-31 |
| 10478432 | Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain P. Vasserot +5 more | 2019-11-19 |
| 10478433 | Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss | Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker +5 more | 2019-11-19 |
| 10413542 | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase | Remi-Martin Laberge, Nathaniel David, Alain P. Vasserot, Darren J. Baker, Bennett G. Childs +3 more | 2019-09-17 |
| 10328058 | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques | Darren J. Baker, Marco Demaria, Albert Davalos, Bennett G. Childs, James L. Kirkland +5 more | 2019-06-25 |
| 10328073 | Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells | Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain P. Vasserot +5 more | 2019-06-25 |
| 10258618 | Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen | Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker +3 more | 2019-04-16 |
| 10251376 | Increasing healthy lifespan and delaying progression of age-related phenotypes by selectively removing senescent cells | James L. Kirkland, Tamar Tchkonia, Darren J. Baker | 2019-04-09 |
| 10010546 | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain P. Vasserot +5 more | 2018-07-03 |
| 9993472 | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 | Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David +7 more | 2018-06-12 |
| 9980962 | Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease | Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker +3 more | 2018-05-29 |
| 9968076 | Transgenic animals capable of being induced to delete senescent cells | James L. Kirkland, Tamar Tchkonia, Darren J. Baker | 2018-05-15 |
| 7220892 | Transgenic mouse lacking PAPP-A activity | Cheryl A. Conover | 2007-05-22 |
| 7098377 | IEX-1 knockout animals | Rajiv Kumar | 2006-08-29 |